Greg founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® Consulting has worked with over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences focused on investment and partnering, including the highly successful ChinaBio® Partnering Forum which draws over 800 attendees from around the world to China each spring. Greg is also co-founder of two angel investment groups (BioPacific Investors and Life Science Angels) which have funded over 50 biotechnology and medical device companies in the U.S. and China, and Executive Editor of ChinaBio® Today, the most widely read source for China life science news. Greg lives and works in Shanghai but visits San Diego several times a year to enjoy the blue skies and sandy beaches.
Tom Wu - Vice President, Corporate Development (Shanghai)
Tom is the Vice President, Corporate Development for ChinaBio® Group. He heads ChinaBio corporate development efforts including corporate, government, partner and investor relations. He also leads ChinaBio's conference business and has been responsible for all of our events since 2008. After seven years, Tom left to join Centrillion Technologies, a US genomic sequencing chips company, to build their presence in China. After successfully launching their Hangzhou business operations. In 2017, he returned to ChinaBio to assume expanded responsibilities. He brings many years of experience with cross-border organizations interfacing with China business, having previously run conference and publishing efforts for companies in Canada and Australia. Tom holds a Masters Degree in Management and Marketing from Nottingham Business School in the UK and received the Project Management Certificate from Shanghai Jiao Tong University.
Tracy T. Yeo, PhD - Managing Director, Consulting (San Diego)
As the Managing Director for ChinaBio’s strategic consulting practice, Dr. Yeo brings extensive biomedical research and management consulting experience to our projects. Prior to joining ChinaBio, Tracy was a key team member on over 20 strategic management consulting projects with major life science companies on worldwide commercialization, partnership, product and clinical development strategies for the China and global markets. Tracy holds a PhD in Biomedical Sciences from the City University of New York and received postdoctoral trainings at UCLA and UCSF. She was the recipient of several research awards including the NIH Shannon Director’s Award, UCSF Academic Senate Award, and the Ross Fellowship from the John Douglas French Foundation for Alzheimer’s Research.
Robert Narquizian, PhD, MBA – Senior Advisor (Basel)
Dr. Narquizian support's ChinaBio's financial advisory business, providing both deep scientific and transaction expertise to our team, having led the largest cross-border licensing deal in China. Previously, Robert was based in Shanghai with Eli Lilly as head of Global External R&D China, where he oversaw all of Lilly's cross-border transactions. Previously, at F. Hoffmann-La Roche in Basel, Robert had several roles covering the entire value chain from discovery to partnering. He is also co-author of more than 50 patents and publications and shares inventorship of several molecules that have proceeded into the clinic. Robert graduated with a PhD in Chemistry from the University of Glasgow, a post-doc from the University of Harvard and he also holds an MBA from the London Business School.
Dongxu (Don) Qiu, PhD, MBA - Senior Advisor (Tianjin/Suzhou)
Dr. Qiu has been involved with ChinaBio since its inception in 2007, as the former GM of China, and now as a senior advisor to the company and our investment activities. Don brings extensive management experience in the biotech industry, including research, product development, business development, operations, technology transfer, and venture capital. He has co-founded three successful life science companies in China in services and drug development. He was previously CEO/GM of several China-based biopharma companies and head of China operations for MDS Capital. He holds a PhD in Medicinal Chemistry from Peking University and an MBA from the Richard Ivey School of Business, University of Western Ontario.
Richard Daverman, PhD - Business Editor, ChinaBio® Today (San Diego)
Dr. Daverman brings over 25 years of investment management and publishing experience to ChinaBio® Today and leads the development of our editorial content. Dr. Daverman has been an editor and author for business and scientific publications including the BIOMASS Group, Business Tennessee, AtTheClose.com, and Execucom. He also has experience as a financial manager and stockbroker for Prudential-Bache and Robert Thomas Securities. Dr. Daverman received his PhD from University of Michigan and served on the faculty of Texas A&M University and Universite d'Angers (France).
Jean Meng - Business Director (Shanghai)
Jean was our first employee and runs ChinaBio's business operations. She is the key representative with suppliers supporting our events and all of our efforts in China. Prior to joining ChinaBio, Jean had several years experience helping launch startup companies in China. Jean graduated from the University of Shanghai for Science and Technology.
Claire Feng, JD - Advisor, Legal Affairs (Shanghai)
Claire guides ChinaBio in its legal affairs, assisting in bi-lingual contract negotiations and advising on corporate matters both in the US and China. Her experience includes government affairs, corporate/JV formation, contract negotiation and IP law in China and the US. She was previously a member of the legal staff at Perkins Coie LLP in Beijing and Shanghai, worked with Wilson Sonsini Goodrich & Rosati and the California Attorney General’s Office, and clerked for the California Superior Court. Claire graduated Summa Cum Laude from Thomas Jefferson School of Law in San Diego and holds an LLB degree from Renmin University in Beijing.
Ker Gibbs, MBA – Investment Advisor (Shanghai)
Ker is a private equity investor who has been located in Shanghai for over 12 years. He brings a strong focus in finance with significant experience in investment banking, most recently with HSBC and the Hina Group. having advised on M&A, funding and IPO transactions involving public, private, and state owned enterprises in China. Ker previously held senior management positions in technology, media and consulting comapnies including Apple, McAfee, Disney, NBC and Boston Consulting Group. He is on the investment committee for the angel investment group, BioPacific Investors, and serves on the board of the American Chamber of Commerce in Shanghai. Ker holds an MBA from UC Berkeley and BA in Economics from UCLA. He is fluent in Mandarin, including reading and writing.
David G. Mohler, MD - Investment Advisor (Silicon Valley)
Dr. Mohler ("Doc Mohler") is a renowned surgeon and angel investor based in Silicon Valley. He currently serves as the Chief of the Orthopaedic Tumor Center and Clinical Professor, Orthopaedic Surgery at Stanford University Medical Center in Palo Alto, California. He is also President of the Refugee Relief International, Inc., and travels globally providing medical care to the needy wherever they may be. Dr. Mohler has been investing in early stage life science companies for many years, and serves on the investment committee at BioPacific Investors. His MD is from Cornell University Medical College, with Fellowships at Memorial Sloan-Kettering and UCLA. He received his BS from Stanford University.
Debra Yu, MD – Investment Advisor (NY/Boston)
Dr. Yu is the founder and Managing Director of Labrador Advisors, a consulting firm focused on China-US investment and transactions. She brings over 20 years of experience in the life sciences industry and possesses a unique combination of skills, having worked in venture capital, business development, corporate strategy, investment banking and management consulting. Debra was formerly the SVP of Strategy with Wuxi Apptec, and General Partner Bay City Capital and Delphi Ventures. Previously she was in a number of roles at Pfizer and played a key role in the creation of Pfizer Ventures. She began her career at Morgan Stanley and McKinsey & Co. Debra received a BA with high honors in Molecular Biology from Princeton and earned an MD from Harvard Medical School.